Press Releases
Samsung Biologics to attend series of global conferences to showcase enhanced capabilities
Samsung Biologics will be attending CPHI Worldwide in Milan between October 8-10 for a series of meetings with existing and potential clients on how the company can support their pipelines.
At booth #5B33, the company will highlight its enhanced CDMO capabilities and service offerings regarding various modalities, including Multispecific antibodies, complex molecules, ADC, and mRNA.
Samsung Biologics will also share developments regarding the construction of Plant 5, which will be operational by April 2025. The company is poised to offer a total capacity of 784 kL when complete. Samsung Biologics is also building a dedicated ADC facility that will be complete by the year’s end.
During October 9-11, the company will attend BioJapan in Yokohama. Samsung Biologics plans to hold networking sessions with global clients on collaboration opportunities to support their development goals. Visit the partnering zone – Room #PTR-5 to meet with our team.
Samsung Biologics will be attending CPHI Worldwide in Milan between October 8-10 for a series of meetings with existing and potential clients on how the company can support their pipelines.
At booth #5B33, the company will highlight its enhanced CDMO capabilities and service offerings regarding various modalities, including Multispecific antibodies, complex molecules, ADC, and mRNA.
Samsung Biologics will also share developments regarding the construction of Plant 5, which will be operational by April 2025. The company is poised to offer a total capacity of 784 kL when complete. Samsung Biologics is also building a dedicated ADC facility that will be complete by the year’s end.
During October 9-11, the company will attend BioJapan in Yokohama. Samsung Biologics plans to hold networking sessions with global clients on collaboration opportunities to support their development goals. Visit the partnering zone – Room #PTR-5 to meet with our team.